Eintrag weiter verarbeiten
Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis
Gespeichert in:
| Zeitschriftentitel: | Arthritis & Rheumatism |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Arthritis & Rheumatism, 54, 2006, 1, S. 76-81 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Catrina, Anca Irinel Klint, Erik af Ernestam, Sofia Catrina, Sergiu‐Bogdan Makrygiannakis, Dimitrios Botusan, Ileana Ruxandra Klareskog, Lars Ulfgren, Ann‐Kristin Catrina, Anca Irinel Klint, Erik af Ernestam, Sofia Catrina, Sergiu‐Bogdan Makrygiannakis, Dimitrios Botusan, Ileana Ruxandra Klareskog, Lars Ulfgren, Ann‐Kristin |
|---|---|
| author |
Catrina, Anca Irinel Klint, Erik af Ernestam, Sofia Catrina, Sergiu‐Bogdan Makrygiannakis, Dimitrios Botusan, Ileana Ruxandra Klareskog, Lars Ulfgren, Ann‐Kristin |
| spellingShingle |
Catrina, Anca Irinel Klint, Erik af Ernestam, Sofia Catrina, Sergiu‐Bogdan Makrygiannakis, Dimitrios Botusan, Ileana Ruxandra Klareskog, Lars Ulfgren, Ann‐Kristin Arthritis & Rheumatism Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis Pharmacology (medical) Immunology Rheumatology Immunology and Allergy |
| author_sort |
catrina, anca irinel |
| spelling |
Catrina, Anca Irinel Klint, Erik af Ernestam, Sofia Catrina, Sergiu‐Bogdan Makrygiannakis, Dimitrios Botusan, Ileana Ruxandra Klareskog, Lars Ulfgren, Ann‐Kristin 0004-3591 1529-0131 Wiley Pharmacology (medical) Immunology Rheumatology Immunology and Allergy http://dx.doi.org/10.1002/art.21528 <jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Treatment of rheumatoid arthritis (RA) with tumor necrosis factor (TNF)–blocking agents, including etanercept and infliximab, has resulted in reductions in the radiographic progression of RA. However, the exact mechanism by which this protection occurs has not been determined. In order to add to such knowledge, we investigated the effect of anti‐TNF therapy on the expression of osteoprotegerin (OPG) and receptor activator of NF‐κB ligand (RANKL) in synovial tissue.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The expression of OPG and RANKL in synovial biopsy specimens was evaluated by immunohistochemistry. Serial synovial biopsy specimens were obtained from 18 patients with RA, before and after treatment with etanercept (9 patients) or infliximab (9 patients). Biopsy specimens were evaluated by double‐blind semiquantitative analysis and image analysis. The in vitro effect of TNF antagonists on the RANKL/OPG expression in osteoblasts and endothelial cells was evaluated by Western blotting. Statistical analysis was performed using Wilcoxon's signed rank test, followed by the Bonferroni correction for multiple comparisons of paired samples. The results of in vitro experiments were evaluated by one‐way analysis of variance, with Tukey's post hoc test.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Treatment with both infliximab and etanercept increased the expression of OPG in synovial tissue. After 8 weeks of treatment, neither infliximab nor etanercept influenced RANKL expression. In both groups of patients, the RANKL:OPG ratio decreased following therapy. In vitro, both of the TNF antagonists mimicked the in vivo effect, inducing a decrease in the RANKL:OPG ratio in TNF‐primed osteoblasts and endothelial cells.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Therapy with TNF antagonists in RA modulates the OPG/RANKL system, a potential mechanism that could explain the retardation of radiographic damage observed following anti‐TNF therapy.</jats:p></jats:sec> Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis Arthritis & Rheumatism |
| doi_str_mv |
10.1002/art.21528 |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuMjE1Mjg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuMjE1Mjg |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2006 |
| imprint_str_mv |
Wiley, 2006 |
| issn |
0004-3591 1529-0131 |
| issn_str_mv |
0004-3591 1529-0131 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
catrina2006antitumornecrosisfactortherapyincreasessynovialosteoprotegerinexpressioninrheumatoidarthritis |
| publishDateSort |
2006 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Arthritis & Rheumatism |
| source_id |
49 |
| title |
Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_unstemmed |
Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_full |
Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_fullStr |
Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_full_unstemmed |
Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_short |
Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_sort |
anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| topic |
Pharmacology (medical) Immunology Rheumatology Immunology and Allergy |
| url |
http://dx.doi.org/10.1002/art.21528 |
| publishDate |
2006 |
| physical |
76-81 |
| description |
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Treatment of rheumatoid arthritis (RA) with tumor necrosis factor (TNF)–blocking agents, including etanercept and infliximab, has resulted in reductions in the radiographic progression of RA. However, the exact mechanism by which this protection occurs has not been determined. In order to add to such knowledge, we investigated the effect of anti‐TNF therapy on the expression of osteoprotegerin (OPG) and receptor activator of NF‐κB ligand (RANKL) in synovial tissue.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The expression of OPG and RANKL in synovial biopsy specimens was evaluated by immunohistochemistry. Serial synovial biopsy specimens were obtained from 18 patients with RA, before and after treatment with etanercept (9 patients) or infliximab (9 patients). Biopsy specimens were evaluated by double‐blind semiquantitative analysis and image analysis. The in vitro effect of TNF antagonists on the RANKL/OPG expression in osteoblasts and endothelial cells was evaluated by Western blotting. Statistical analysis was performed using Wilcoxon's signed rank test, followed by the Bonferroni correction for multiple comparisons of paired samples. The results of in vitro experiments were evaluated by one‐way analysis of variance, with Tukey's post hoc test.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Treatment with both infliximab and etanercept increased the expression of OPG in synovial tissue. After 8 weeks of treatment, neither infliximab nor etanercept influenced RANKL expression. In both groups of patients, the RANKL:OPG ratio decreased following therapy. In vitro, both of the TNF antagonists mimicked the in vivo effect, inducing a decrease in the RANKL:OPG ratio in TNF‐primed osteoblasts and endothelial cells.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Therapy with TNF antagonists in RA modulates the OPG/RANKL system, a potential mechanism that could explain the retardation of radiographic damage observed following anti‐TNF therapy.</jats:p></jats:sec> |
| container_issue |
1 |
| container_start_page |
76 |
| container_title |
Arthritis & Rheumatism |
| container_volume |
54 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792337380693245958 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:15:25.484Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Anti%E2%80%93tumor+necrosis+factor+therapy+increases+synovial+osteoprotegerin+expression+in+rheumatoid+arthritis&rft.date=2006-01-01&genre=article&issn=1529-0131&volume=54&issue=1&spage=76&epage=81&pages=76-81&jtitle=Arthritis+%26+Rheumatism&atitle=Anti%E2%80%93tumor+necrosis+factor+therapy+increases+synovial+osteoprotegerin+expression+in+rheumatoid+arthritis&aulast=Ulfgren&aufirst=Ann%E2%80%90Kristin&rft_id=info%3Adoi%2F10.1002%2Fart.21528&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792337380693245958 |
| author | Catrina, Anca Irinel, Klint, Erik af, Ernestam, Sofia, Catrina, Sergiu‐Bogdan, Makrygiannakis, Dimitrios, Botusan, Ileana Ruxandra, Klareskog, Lars, Ulfgren, Ann‐Kristin |
| author_facet | Catrina, Anca Irinel, Klint, Erik af, Ernestam, Sofia, Catrina, Sergiu‐Bogdan, Makrygiannakis, Dimitrios, Botusan, Ileana Ruxandra, Klareskog, Lars, Ulfgren, Ann‐Kristin, Catrina, Anca Irinel, Klint, Erik af, Ernestam, Sofia, Catrina, Sergiu‐Bogdan, Makrygiannakis, Dimitrios, Botusan, Ileana Ruxandra, Klareskog, Lars, Ulfgren, Ann‐Kristin |
| author_sort | catrina, anca irinel |
| container_issue | 1 |
| container_start_page | 76 |
| container_title | Arthritis & Rheumatism |
| container_volume | 54 |
| description | <jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Treatment of rheumatoid arthritis (RA) with tumor necrosis factor (TNF)–blocking agents, including etanercept and infliximab, has resulted in reductions in the radiographic progression of RA. However, the exact mechanism by which this protection occurs has not been determined. In order to add to such knowledge, we investigated the effect of anti‐TNF therapy on the expression of osteoprotegerin (OPG) and receptor activator of NF‐κB ligand (RANKL) in synovial tissue.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The expression of OPG and RANKL in synovial biopsy specimens was evaluated by immunohistochemistry. Serial synovial biopsy specimens were obtained from 18 patients with RA, before and after treatment with etanercept (9 patients) or infliximab (9 patients). Biopsy specimens were evaluated by double‐blind semiquantitative analysis and image analysis. The in vitro effect of TNF antagonists on the RANKL/OPG expression in osteoblasts and endothelial cells was evaluated by Western blotting. Statistical analysis was performed using Wilcoxon's signed rank test, followed by the Bonferroni correction for multiple comparisons of paired samples. The results of in vitro experiments were evaluated by one‐way analysis of variance, with Tukey's post hoc test.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Treatment with both infliximab and etanercept increased the expression of OPG in synovial tissue. After 8 weeks of treatment, neither infliximab nor etanercept influenced RANKL expression. In both groups of patients, the RANKL:OPG ratio decreased following therapy. In vitro, both of the TNF antagonists mimicked the in vivo effect, inducing a decrease in the RANKL:OPG ratio in TNF‐primed osteoblasts and endothelial cells.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Therapy with TNF antagonists in RA modulates the OPG/RANKL system, a potential mechanism that could explain the retardation of radiographic damage observed following anti‐TNF therapy.</jats:p></jats:sec> |
| doi_str_mv | 10.1002/art.21528 |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuMjE1Mjg |
| imprint | Wiley, 2006 |
| imprint_str_mv | Wiley, 2006 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0004-3591, 1529-0131 |
| issn_str_mv | 0004-3591, 1529-0131 |
| language | English |
| last_indexed | 2024-03-01T15:15:25.484Z |
| match_str | catrina2006antitumornecrosisfactortherapyincreasessynovialosteoprotegerinexpressioninrheumatoidarthritis |
| mega_collection | Wiley (CrossRef) |
| physical | 76-81 |
| publishDate | 2006 |
| publishDateSort | 2006 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Arthritis & Rheumatism |
| source_id | 49 |
| spelling | Catrina, Anca Irinel Klint, Erik af Ernestam, Sofia Catrina, Sergiu‐Bogdan Makrygiannakis, Dimitrios Botusan, Ileana Ruxandra Klareskog, Lars Ulfgren, Ann‐Kristin 0004-3591 1529-0131 Wiley Pharmacology (medical) Immunology Rheumatology Immunology and Allergy http://dx.doi.org/10.1002/art.21528 <jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Treatment of rheumatoid arthritis (RA) with tumor necrosis factor (TNF)–blocking agents, including etanercept and infliximab, has resulted in reductions in the radiographic progression of RA. However, the exact mechanism by which this protection occurs has not been determined. In order to add to such knowledge, we investigated the effect of anti‐TNF therapy on the expression of osteoprotegerin (OPG) and receptor activator of NF‐κB ligand (RANKL) in synovial tissue.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The expression of OPG and RANKL in synovial biopsy specimens was evaluated by immunohistochemistry. Serial synovial biopsy specimens were obtained from 18 patients with RA, before and after treatment with etanercept (9 patients) or infliximab (9 patients). Biopsy specimens were evaluated by double‐blind semiquantitative analysis and image analysis. The in vitro effect of TNF antagonists on the RANKL/OPG expression in osteoblasts and endothelial cells was evaluated by Western blotting. Statistical analysis was performed using Wilcoxon's signed rank test, followed by the Bonferroni correction for multiple comparisons of paired samples. The results of in vitro experiments were evaluated by one‐way analysis of variance, with Tukey's post hoc test.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Treatment with both infliximab and etanercept increased the expression of OPG in synovial tissue. After 8 weeks of treatment, neither infliximab nor etanercept influenced RANKL expression. In both groups of patients, the RANKL:OPG ratio decreased following therapy. In vitro, both of the TNF antagonists mimicked the in vivo effect, inducing a decrease in the RANKL:OPG ratio in TNF‐primed osteoblasts and endothelial cells.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Therapy with TNF antagonists in RA modulates the OPG/RANKL system, a potential mechanism that could explain the retardation of radiographic damage observed following anti‐TNF therapy.</jats:p></jats:sec> Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis Arthritis & Rheumatism |
| spellingShingle | Catrina, Anca Irinel, Klint, Erik af, Ernestam, Sofia, Catrina, Sergiu‐Bogdan, Makrygiannakis, Dimitrios, Botusan, Ileana Ruxandra, Klareskog, Lars, Ulfgren, Ann‐Kristin, Arthritis & Rheumatism, Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis, Pharmacology (medical), Immunology, Rheumatology, Immunology and Allergy |
| title | Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_full | Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_fullStr | Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_full_unstemmed | Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_short | Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_sort | anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| title_unstemmed | Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis |
| topic | Pharmacology (medical), Immunology, Rheumatology, Immunology and Allergy |
| url | http://dx.doi.org/10.1002/art.21528 |